Skip to Content

Posts tagged with "Drug Prices"

  • Alzheimer's Disease

    There Are Failures, You Know

    This exact point came up around here when we last discussed FDA reform, so it’s good to see it made at length in the New England Journal of Medicine. Remember solanezumab? That was the amyloid-targeting antibody that Eli Lilly kept on investigating in trial after trial, looking for some effect on Alzheimer’s. Last November, the final… Read More
  • Business and Markets

    Marathon’s Real Costs

    Endpoints has done a great breakdown on the actual costs that Marathon Pharmaceuticals is likely to have incurred while bringing their wildly overpriced old generic steroid to the US market. They did no new registrational studies in the clinic, in case you’re wondering. There was a drug-drug interaction study, ADME work, that sort of thing… Read More
  • Drug Prices

    The Case of Marathon Pharmaceuticals

    So since drug pricing and FDA regulations are so much in the news, it would seem like the perfect time for a small company to game the system for big profits, right? That’s apparently what Marathon Pharmaceuticals believes. They just got approval for deflazacort, a steroid, as a treatment for Duchenne Muscular Dystrophy. Duchenne is… Read More
  • Academia (vs. Industry)

    A Call For Academic Drug Companies

    An editorial in Cell asks “How Much Longer Will We Put Up With $100,000 Cancer Drugs?” I’m of two minds on questions like that. OK, three minds. The immediate impulse, not an honorable one, is to respond with pure snark, which is always tempting, in the vein of “If you can keep your company going… Read More
  • Drug Prices

    Those Australian Students And Their Daraprim

    OK, enough people have emailed me the press coverage of the students in Sydney making daraprim, which is the drug that Martin Shkreli’s former firm has famously jacked up the price of. From what I can see, a lot of the news stories on this are missing the point. Daraprim is not hard to make in… Read More
  • Business and Markets

    More from the Drugs for Neglected Disease Initiative

    My recent post on the Drugs for Neglected Diseases Initiative (DNDi) brought some emails from Robert Don at the organization. He has more details on the sleeping sickness project – pointing out, for example, that the contribution from Scynexis was not pro bono, as I’d assumed: We actually contracted a team of 10 chemists at… Read More
  • Business and Markets

    Read These Before You Write That Op-Ed

    I’m conferencing today in Manchester, with less time to blog than usual. But I wanted to strongly recommend a couple of other posts this morning: first off, Bruce Booth’s on innovation and its flip side, exploitation, in the drug business. A good complementary post is this one at SlateStarCodex, which goes into detail, with great… Read More
  • Business and Markets

    The Impact of Various Countries on Biopharma – Or Not

    Here’s a report looking at biopharma by country, and ranking countries based on how good an environment they provide for the industry. The three big criteria are how much their governments spend on R&D, specifically life sciences and medical R&D, how closely they regulate pharmaceutical prices, and how strong their intellectual proper… Read More
  • Drug Prices

    Generics Get Cheaper, As They Should

    Here’s a useful perspective from Alex Tabarrok at Marginal Revolution: several recent studies have concluded that, over the last several years, generic drug prices as a whole have continued to decrease. That’s how it’s supposed to be: all those prescription drugs whose prices seem ridiculous are (eventually) doomed. They’ll… Read More
  • Drug Prices

    Update on Catalyst Pharmaceuticals

    I wanted to update readers on Catalyst Pharmaceuticals, whom I first wrote about here. They’re the ones who have been planning 3,4-diaminopyridine (DAP), a therapy for a rare disorder called Lambert-Eaton Myasthenic Syndrome which is currently being provided at no cost, and run it through the FDA’s regulatory process so as to get market… Read More
123...